drugset / Trial / NCT01667731

Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

NCT01667731

Phase 3 Completed 224 enrolled Gilead Sciences
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy, safety, and tolerability of sofosbuvir (SOF; GS-7977) plus ribavirin (RBV) in adults with chronic genotypes 1, 2, and 3 HCV infection who are coinfected with HIV-1.

Timeline

Start
2012-07
Primary completion
2013-11
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 1000 mg Oral
Subject Ribavirin Small molecule 1200 mg Oral
Subject Sofosbuvir Small molecule 400 mg Oral